KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Retained Earnings (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Retained Earnings data on record, last reported at $56000.0 in Q3 2025.

  • For Q3 2025, Retained Earnings rose 100.0% year-over-year to $56000.0; the TTM value through Sep 2025 reached $56000.0, up 100.0%, while the annual FY2024 figure was $61000.0, 23.75% down from the prior year.
  • Retained Earnings reached $56000.0 in Q3 2025 per NKTR's latest filing, up from -$3.7 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $80000.0 in Q4 2023 and bottomed at -$3.7 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$689.7 million, with a median of -$5.7 million recorded in 2023.
  • The widest YoY moves for Retained Earnings: up 109.68% in 2025, down 746597.37% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$4.2 million in 2021, then crashed by 76907.29% to -$3.2 billion in 2022, then skyrocketed by 100.0% to $80000.0 in 2023, then fell by 23.75% to $61000.0 in 2024, then dropped by 8.2% to $56000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $56000.0 in Q3 2025, -$3.7 billion in Q2 2025, and $39000.0 in Q1 2025.